ARTICLE | Clinical News
Methylnaltrexone regulatory update
July 25, 2016 7:00 AM UTC
FDA approved an NDA from Valeant for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Valeant expects to launch the drug this quarter. The approval triggered a $50 million milestone payment to Progenics from Valeant, which gained worldwide rights to Relistor, excluding Japan, through its 2015 acquisition of Salix Pharmaceuticals Ltd. Salix had rights to the product from Progenics under a 2011 deal. ...